Adial Pharmaceuticals appoints David Rubenstein as Chief Scientist
What happened
Adial Pharmaceuticals, Inc. announced the appointment of David Rubenstein as Chief Scientist following its acquisition of Azora Therapeutics. Rubenstein will lead the company's research and scientific strategy, including the continued study of AT177, an oral aryl hydrocarbon receptor (AhR) agonist for ulcerative colitis.
From manilatimes.net
Why it matters
Rubenstein previously guided tapinarof, the first AhR agonist, through development, approval, and commercialization for plaque psoriasis and atopic dermatitis. His experience establishes AhR agonism as a clinically proven mechanism in immune-mediated inflammatory disease.
From manilatimes.net
Who's involved
- David RubensteinAppointed Chief Scientist to lead research and scientific strategy at Adial Pharmaceuticals, Inc.
- FDARegulatory body whose approval process Rubenstein previously navigated for AhR agonists
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- United States of AmericaSpeculative
The pharmaceutical industry might see increased investment in AhR agonist treatments if AT177 progresses toward regulatory approval.
Keep exploring
The entities involved
- FDA
-
David Rubenstein
American businessman (born 1949)
Nothing else this week.
Related events
- Arise is seeking FDA approval for a drug as of October 7, 2026.
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
- FDA is willing to review updated submissions, while biotech hubs leverage AI to ease clinical development bottlenecks.
- FDA provided guidance for HCW Biologics' IND application.
- FDA approval is the goal for product candidates from Daré Bioscience, Inc.